AdAlta’s (ASX: 1AD) CEO and Managing Director, Dr Tim Oldham presented at the virtual Emerging Growth Conference on Thursday 13 July. This small cap conference is designed to present emerging growth companies to investment communities across the US and the world.
Dr Oldham’s presentation provided an overview of AdAlta and the Company’s pipeline and partnering opportunities, following the release of a positive quarterly report. Click below to watch the presentation and the Q&A session. The highlights include:
- New data released 7 July favourably links AD-214 preclinical animal studies and Phase I human trial results with efficacy for the first time, de-risking the clinical dosing schedule
- A highly productive BIO2023 partnering conference progressed partnering interest and discussions in AD-214, plus two additional opportunities
- The successful completion of the recent Rights Offer, raising $1.28 million with an additional $1.87 million committed in an oversubscribed shortfall facility
- The Phase I extension study for AD-214, to reduce the duration and cost of Phase II recently received ethics approval and is starting soon